Is Repligen (RGEN) Offering Value After A 28.5% Year To Date Share Price Decline

Simply Wall St.

Apr 30

If you are wondering whether Repligen at around US$117 a share offers good value or hidden risks, the next sections break down what the current price may be implying. The stock has had a mixed run, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2631854207"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631854207\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631854207?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-04-30 01:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631854207","market":"nz","top_or_hot":-1,"title":"Is Repligen (RGEN) Offering Value After A 28.5% Year To Date Share Price Decline","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Repligen at around US$117 a share offers good value or hidden risks, the next sections break down what the current price may be implying. The stock has had a mixed run, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/is-repligen-rgen-offering-value-after-a-285-year-to-date-sha\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Repligen (RGEN) Offering Value After A 28.5% Year To Date Share Price Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Repligen (RGEN) Offering Value After A 28.5% Year To Date Share Price Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-30 01:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/is-repligen-rgen-offering-value-after-a-285-year-to-date-sha><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Repligen at around US$117 a share offers good value or hidden risks, the next sections break down what the current price may be implying. The stock has had a mixed run, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/is-repligen-rgen-offering-value-after-a-285-year-to-date-sha\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1815336091.USD","symbol_name":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/is-repligen-rgen-offering-value-after-a-285-year-to-date-sha","article_id":"2631854207","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/is-repligen-rgen-offering-value-after-a-285-year-to-date-sha","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2631854207","pubTimestamp":1777482401,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Repligen at around US$117 a share offers good value or hidden risks, the next sections break down what the current price may be implying.\nThe stock has had a mixed run, with a 6.6% gain over the last 30 days, set against a 28.5% decline year to date and a 15.8% decline over the past year.\nThese moves sit within a broader three year return of 25.3% decline and a five year return of 39.7% decline. This can influence how the market currently views the stock's risk...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4121":"生命科学工具和服务","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","RGEN":"Repligen Corporation","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV"},"translate_title":"Repligen(RGEN)股价今年迄今下跌28.5%后是否有价值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGEN":1.5,"DCF":1},"content_text":"If you are wondering whether Repligen at around US$117 a share offers good value or hidden risks, the next sections break down what the current price may be implying. The stock has had a mixed run, with a 6.6% gain over the last 30 days, set against a 28.5% decline year to date and a 15.8% decline over the past year. These moves sit within a broader three year return of 25.3% decline and a five year return of 39.7% decline. This can influence how the market currently views the stock's risk and reward trade off. Understanding that context helps when comparing today’s valuation to where the share price has been over different time frames. Repligen currently has a value score of 3 out of 6. The rest of this article will walk through how different valuation methods line up with that score, before finishing with a way to look at value that goes beyond the usual multiples and models.  Find out why Repligen's -15.8% return over the last year is lagging behind its peers. AdvertisementApproach 1: Repligen Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes estimates of the cash a business could generate in the future and discounts those back to today, aiming to arrive at an estimate of what the entire company might be worth now. For Repligen, the model uses last twelve month free cash flow of about $81.5 million as a starting point and then applies analyst projections and extrapolated figures. Analyst estimates run out to 2029, with Simply Wall St extending the forecast through 2035 using its own growth assumptions. By 2030, annual free cash flow is projected at $364.7 million. All of these future cash flows are discounted back using a 2 Stage Free Cash Flow to Equity model. This produces an estimated intrinsic value of about $169.13 per share. Compared with the current share price of around $117, the DCF output suggests the stock trades at about a 30.6% discount. This indicates potential upside according to this model. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Repligen is undervalued by 30.6%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks. RGEN Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Repligen. Approach 2: Repligen Price vs Earnings For profitable companies, the P/E ratio is a useful way to link what you pay for each share to the earnings that support that price. It gives you a quick sense of how many years of current earnings the market is effectively paying for. What counts as a “normal” P/E depends on how the market views a company’s growth potential and risk. Higher expected growth and lower perceived risk can justify a higher multiple, while slower growth or higher risk usually go with a lower multiple. Repligen currently trades on a P/E of about 135.46x. That is well above the Life Sciences industry average of roughly 34.40x and also above the peer group average of about 35.70x. To go beyond simple comparisons, Simply Wall St uses a proprietary “Fair Ratio” for Repligen of 24.18x. This metric aims to reflect what P/E might make sense after considering factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because the Fair Ratio adjusts for these elements, it offers a more tailored benchmark than broad industry or peer averages. Comparing the current 135.46x P/E with the 24.18x Fair Ratio suggests the shares are pricing in a much richer multiple than this framework supports. Result: OVERVALUED NasdaqGS:RGEN P/E Ratio as at Apr 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies. Upgrade Your Decision Making: Choose your Repligen Narrative Earlier it was mentioned that there is an even better way to understand valuation, so meet Narratives, a simple way for you to attach a clear story about Repligen to the numbers you think are reasonable for its future revenue, earnings, margins and fair value. A Narrative on Simply Wall St links three things together: your view of Repligen's business story, a forecast that reflects that view, and a resulting fair value that you can compare directly with the current share price to help you decide whether the stock looks expensive or attractive on your assumptions. These Narratives are available on the Community page of Simply Wall St, where millions of investors share and review different fair values for Repligen, and the platform keeps each Narrative updated automatically when fresh information such as earnings or news is added to the company profile. For example, one Repligen Narrative currently anchors on a fair value of about US$140, reflecting more cautious assumptions, while another sits closer to US$220, which is more optimistic. By comparing those to the recent price around US$117 you can see how different views on the same company lead to very different conclusions about value. Do you think there's more to the story for Repligen? Head over to our Community to see what others are saying! NasdaqGS:RGEN 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}